Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

References

• ShirzadiAAGhaemiSNSide effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndromeHarv Rev Psychiatry20061415216416787887
   PubMed Web of Science ®Google Scholar
• BarnesTRMcPhillipsMANovel antipsychotics, extrapyramidal side effects and tardive dyskinesiaInt Clin Psychopharmacol199813Suppl 3S49S579690971
   PubMed Web of Science ®Google Scholar
• LeoRJRegnoPDAtypical antipsychotic use in the treatment of psychosis in primary carePrim Care Companion J Clin Psychiatry2000219420415014629
   PubMedGoogle Scholar
• GlazerWMExtrapyramidal side effects, tardive dyskinesia, and the concept of atypicalityJ Clin Psychiatry200061Suppl 3162110724129
   PubMed Web of Science ®Google Scholar
• WeidenPJEPS profiles: the atypical antipsychotics are not all the sameJ Psychiatr Pract200713132417242588
   PubMedGoogle Scholar
• EreshefskyLWatanabeMDTran-JohnsonTKClozapine: an atypical antipsychotic agentClin Pharm198986917092572373
   PubMedGoogle Scholar
• KaneJMFleischhackerWWHansenLPerlisRPikalovA3rdAssuncao-TalbottSAkathisia: an updated review focusing on second-generation antipsychoticsJ Clin Psychiatry20097062764319389331
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet2009373314119058842
   PubMed Web of Science ®Google Scholar
• MillerCHMohrFUmbrichtDWoernerMFleischhackerWWLiebermanJAThe prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychoticsJ Clin Psychiatry19985969759501888
   PubMed Web of Science ®Google Scholar
• PierreJMExtrapyramidal symptoms with atypical antipsychotics: incidence, prevention and managementDrug Saf20052819120815733025
   PubMed Web of Science ®Google Scholar
• CitromeLPaliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medicationInt J Clin Pract20106421623919886879
   PubMed Web of Science ®Google Scholar
• McCreaMPliskinNBarthJOfficial position of the military TBI task force on the role of neuropsychology and rehabilitation psychology in the evaluation, management, and research of military veterans with traumatic brain injuryClin Neuropsychol200822102618247218
   PubMed Web of Science ®Google Scholar
• SimpsonGMLindenmayerJPExtrapyramidal symptoms in patients treated with risperidoneJ Clin Psychopharmacol1997171942019169965
   PubMed Web of Science ®Google Scholar
• DavidsonMEmsleyRKramerMEfficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled studySchizophr Res20079311713017466492
   PubMed Web of Science ®Google Scholar
• GopalSHoughDWXuHEfficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response studyInt Clin Psychopharmacol20102524725620389255
   PubMed Web of Science ®Google Scholar
• KaneJCanasFKramerMTreatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trialSchizophr Res20079014716117092691
   PubMed Web of Science ®Google Scholar
• KramerMLitmanRHoughDPaliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety studyInt J Neuropsychopharmacol20101363564719941696
   PubMed Web of Science ®Google Scholar
• MarderSRKramerMFordLEfficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled studyBiol Psychiatry2007621363137017601495
   PubMed Web of Science ®Google Scholar
• NasrallahHAGopalSGassmann-MayerCA controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophreniaNeuropsychopharmacology2010352072208220555312
   PubMed Web of Science ®Google Scholar
• PandinaGJLindenmayerJPLullJA randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophreniaJ Clin Psychopharmacol20103023524420473057
   PubMed Web of Science ®Google Scholar
• PopeAAdamsCPatonCWeaverTBarnesTRAssessment of adverse effects in clinical studies of antipsychotic medication: survey of methods usedBr J Psychiatry2010197677220592438
   PubMed Web of Science ®Google Scholar
• GuyWAbnormal Involuntary Movement ScaleGuyWECDEU Assessment Manual for PsychopharmacologyRockville, MDUS Dept of Health Education and Welfare1976
   Google Scholar
• GervinMBarnesTREAssessment of drug-related movement disorders in schizophreniaAdv Psychiatr Treat20006332341
   Google Scholar
• SimpsonGMAngusJWA rating scale for extrapyramidal side effectsActa Psychiatr Scand Suppl197021211194917967
   PubMedGoogle Scholar
• BarnesTRA rating scale for drug-induced akathisiaBr J Psychiatry19891546726762574607
   PubMed Web of Science ®Google Scholar
• GopalSBerwaertsJNuamahINumber needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophreniaNeuropsychiatr Dis Treat201179310121552311
   PubMed Web of Science ®Google Scholar
• PotvinSBlanchetPStipESubstance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysisSchizophr Res200911318118819608386
   PubMed Web of Science ®Google Scholar
• KastenMBruggemannNKonigIRRisk for antipsychotic-induced extrapyramidal symptoms: influence of family history and genetic susceptibilityPsychopharmacology (Berl)201121472973621072501
   PubMed Web of Science ®Google Scholar
• LencerREismannGKastenMFamily history of primary movement disorders as a predictor for neuroleptic-induced extrapyramidal symptomsBr J Psychiatry200418546547115572736
   PubMed Web of Science ®Google Scholar
• ChuePEerdekensMAugustynsIComparative efficacy and safety of long-acting risperidone and risperidone oral tabletsEur Neuropsychopharmacol20051511111715572280
   PubMed Web of Science ®Google Scholar
• EmsleyRMedoriRKoenLOosthuizenPPNiehausDJRabinowitzJLong-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary studyJ Clin Psychopharmacol20082821021318344732
   PubMed Web of Science ®Google Scholar
• MollerHJLong-acting injectable risperidone for the treatment of schizophrenia: clinical perspectivesDrugs2007671541156617661527
   PubMed Web of Science ®Google Scholar
• OlivaresJMRodriguez-MoralesADielsJLong-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)Eur Psychiatry20092428729619195847
   PubMed Web of Science ®Google Scholar